# IPATunity130 (NCT03337724)

> A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer

No report yet. It can be ordered.

- Drugs tested: ipatasertib
- Indication: PIK3CA/AKT1/PTEN-altered advanced HER2-negative breast cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03337724
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Breast Cancer
- Interventions: Ipatasertib; Paclitaxel; Placebo
- Enrollment: 579
- Primary outcome: Cohort A: Progression-Free Survival (PFS)
- Primary outcome: Cohort B: PFS
- Primary outcome: Cohort C: PFS

## Indexed commentary on IPATunity130 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 4 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=ipatunity130-nct03337724